Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?

Hepatology

Volumn 58, Issue 1, 2013, Pages 18-20

  Sherman, Morris ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; DRUG POTENCY; DRUG TOLERABILITY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84879606082     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26317     Document Type: Article

References (11)

1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
2. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57: 399-408.
3. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
4. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
5. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-276.
6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al.; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
7. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer D, Deterding K, et al. Virological response to entecavir is associated with better clinical outcomes in chronic hepatitis B patients with cirrhosis. Gut 2012 [Epub ahead of print].
8. Thiele M, Gluud LL, Krage A. Antiviral therapy in hepatitis B has no effect on mortality and decreases incidence of HCC only in patients with cirrhosis. A meta-analysis of 27 trials and 7, 034 patients. HEPATOLOGY 2012; 56( S1): 642A.
9. Lee YS, Loo NM, Larson JJ, St. Sauver J, Kim WR. Community effectiveness in clinical outcome of chronic hepatitis B. Hepatology 2012; 56( S1): 632A.
10. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
11. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.